| 乔建新,王静辉,李媛莉,曹 兵,刘 明,刘熙鹏.低分子肝素钙联合阿加曲班应用于急性脑梗死抗凝治疗对患者疗效和预后的影响[J].,2020,(14):2736-2739 |
| 低分子肝素钙联合阿加曲班应用于急性脑梗死抗凝治疗对患者疗效和预后的影响 |
| The Effect of Low Molecular Weight Heparin Calcium Combined with Agatraban on the Curative Effect and Prognosis of Patients with Acute Cerebral Infarction |
| 投稿时间：2019-12-07 修订日期：2019-12-30 |
| DOI：10.13241/j.cnki.pmb.2020.14.030 |
| 中文关键词: 低分子肝素钙 阿加曲班 急性脑梗死 抗凝 预后 |
| 英文关键词: Low molecular weight heparin calcium Agatraban Acute cerebral infarction Anticoagulation Prognosis |
| 基金项目:河北省医学科学研究重点计划项目（20180814）；张家口市科学技术研究与发展计划项目（132112D） |
|
| 摘要点击次数: 737 |
| 全文下载次数: 401 |
| 中文摘要: |
| 摘要 目的：探讨低分子肝素钙联合阿加曲班应用于急性脑梗死（ACI）抗凝治疗对患者临床疗效和预后的影响。方法：选取我院于2016年1月至2018年12月期间收治的120例ACI患者，采用随机数字表法分为研究组与对照组各60例，对照组采用低分子肝素钙进行抗凝治疗，研究组在对照组基础上联合阿加曲班治疗，对比两组治疗前后的神经功能缺损评分（NIHSS）、巴氏指数（BI）、纤维蛋白原（FIB）、血小板计数（PLT）、血浆黏度值、血清一氧化氮（NO）、一氧化氮合酶（NOS）、血浆内皮祖细胞（EPCs）及患者的预后。结果：治疗14 d后， 两组NIHSS评分、血浆黏度值降低，且研究组低于对照组（P<0.05），BI评分、NO、NOS、EPCs升高，且研究组高于对照组（P<0.05）。治疗14 d后，两组FIB、PLT均较治疗前降低（P<0.05），但两组比较无统计学差异（P>0.05）。研究组的预后良好率为60.00%，显著高于对照组的41.67%（P<0.05）。结论：低分子肝素钙联合阿加曲班应用于ACI抗凝治疗的临床效果较好，可改善患者血管内皮活性和预后，促进患者神经功能的恢复，降低血液黏度。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the effect of low molecular weight heparin calcium combined with agatraban on the clinical efficacy and prognosis of patients with acute cerebral infarction (ACI). Methods: 120 patients with ACI who were admitted to our hospital from January 2016 to December 2018 were slected, they were randomly divided into study group and control group, with 60 cases in each group. The control group was treated with low molecular weight heparin calcium for anticoagulation. The study group was treated with agatraban on the basis of the control group, and the neurological deficit score (NIHSS), Babbitt index (BI) and fiber were compared before and after treatment FIB, PLT, plasma viscosity, no, NOS, EPCs and prognosis. Results: after 14 days of treatment, the NIHSS score and plasma viscosity of the two groups were lower than those of the control group (P<0.05), and the Bi score, no, NOS and EPCs of the study group were higher than those of the control group (P<0.05). After 14 days of treatment, FIB and PLT in both groups were lower than those before treatment (P<0.05), but there was no difference between the two groups (P>0.05). The good prognosis rate of the study group was 60.00%, which was significantly higher than 41.67% of the control group (P<0.05). Conclusion: Low molecular weight heparin calcium combined with agatraban has a good clinical effect in ACI anticoagulation, which can improve the endothelial activity and prognosis, promote the recovery of nerve function and reduce blood viscosity. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
